Newark, DENCT06093906Now EnrollingIRB Ready

Posttraumatic Stress Disorder Clinical Trial in Newark, DE

Access cutting-edge posttraumatic stress disorder treatment through this clinical trial at a research site in Newark. Study-provided care at no cost to qualified participants.

Sponsored by Case Western Reserve University

Quick Self-Assessment

See if you qualify for this Newark location

Preparing your pre-screening questions…

Expert Care in Newark

Access posttraumatic stress disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related posttraumatic stress disorder treatment provided free

Apply for This Newark Location

Check if you qualify for this posttraumatic stress disorder clinical trial in Newark, DE

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Newark

    Convenient for DE residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Newark site if eligible
  4. 4Begin participation

About This Posttraumatic Stress Disorder Study in Newark

The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, this study will examine Positive Processes and Transition to Health (PATH)'s impact on stressor-related psychopathology in comparison to Progressive Muscle Relaxation (PMR). In the R33 phase, the investigators will examine changes in target mechanisms predicting improvements in PTSD and depressive symptoms, as well as feasibility and acceptability. Patients will receive 6 sessions of PATH or PMR (with 2 boosters, if partial responders). Primary targets will be assessed at pre-treatment, week 3, post-treatment, and at 1- and 3-month follow-up; secondary targets at pre-treatment, weekly during treatment, post-treatment, and at 1- and 3-month follow-ups.

Sponsor: Case Western Reserve University

Who Can Participate

Inclusion Criteria

Destabilizing life event involving profound loss or threat, with a minimum duration of 12 weeks since the event, but occurred within the last 5 years.
Between the ages of 18 and 65.
Elevated target: Scores of at least moderate (1 or higher) on at least 2 of the 3 target mechanisms: re- experiencing or ruminative processing of the destabilizing event (PSS-I items: 1, 2, 3, 4 or QIDS-C item 11), avoidance (PSS-I items 6, 7, 8), or reward deficits (PSS-I items 12, 13, or QIDS-C item 13).

Exclusion Criteria

Current diagnosis of schizophrenia, delusional disorder, or organic mental disorder as defined by DSM-5.
Current diagnosis of bipolar disorder, depression with psychotic features, or depression severe enough to require immediate psychiatric treatment (i.e., serious suicide risk with intent and plan).
Severe self-injurious behavior or suicide attempt within the previous three months.
Unwilling or unable to discontinue current cognitive behavioral psychotherapy.
No clear memory of the destabilizing event or event occurred before age 3.
Unstable dose of psychotropic medications in prior 3 months.
Ongoing intimate relationship with the perpetrator (in assault related event).
Current diagnosis of a substance use disorder (DSM-5).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Newark?

Yes, this clinical trial (NCT06093906) has an active research site in Newark, DE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Posttraumatic Stress Disorder Treatment Options in Newark, DE

If you're searching for posttraumatic stress disorder treatment options in Newark, DE, this clinical trial (NCT06093906) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Newark research site is actively enrolling participants for this clinical trial. You'll receive care from experienced posttraumatic stress disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all posttraumatic stress disorder clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Newark, DE

See all rheumatoid arthritis clinical trials recruiting in Newark — not just this study.

Browse Rheumatoid Arthritis Trials in Newark

Ready to Join in Newark?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Newark, DE